Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)
Furosemide
Dechra Limited
QC03CA01
Furosemide
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Cats, Dogs
Cardio Vascular diuretic
Authorized
1998-08-14
Revised: March 2022 AN: 02253/2021 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Frusedale 40 mg Oral Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active ingredient Furosemide (Frusemide) 40 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. White, circular, biconvex, flat-faced tablets with bevelled edges and a breakline. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats and dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of oedema associated with cardiac insufficiency, renal dysfunction and trauma in cats and dogs. In animals with pulmonary oedema of cardiac origin, combined therapy with other medicinal products may be indicated. 4.3 CONTRAINDICATIONS Do not use in animals with acute glomerular nephritis, renal failure with anuria, electrolyte deficiency disease or in animals that have received an overdosage of digitalis. Do not use concurrently with aminoglycoside antibiotics. Do not use in animals weighing less than 4 kg. Revised: March 2022 AN: 02253/2021 Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals Do not exceed the recommended dosage. Therapeutic efficacy may be impaired by increased intake of drinking water. Where the animal’s condition permits, water intake should be restricted during treatment with Frusedale 40 mg oral tablets. Monitoring of plasma potassium levels is advisable during periods of prolonged treatment of combined therapy with cardiac glycosides. Potassium supplements may be necessary. ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Wear gloves, or wash your hands immediately after handling the tablets. iii. Other precautions None. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) During the post-authorisation period and following use of the product in dogs displaying signs of cardiac disease, lethargy, mal Izlasiet visu dokumentu